Overview
NICE is unable to make a recommendation on mirabegron (Betmiga) for treating neurogenic detrusor activity in people 3 to 17 years. This is because the company did not provide an evidence submission.
Last reviewed: 01 October 2025
Next review: We will review this decision if the company decides to make a submission.